Zubsolv (Buprenorphine HCl/Naloxone HCl) Patent Expiration, LOE Window & CMS Spending

Zubsolv (Buprenorphine HCl/Naloxone HCl) by Edenbridge Dba Dexcel Usa: FDA Orange Book LOE 2032-09-18, 11 AB generics, $74.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEdenbridge Dba Dexcel Usa
FDA Application & PathwayN204242 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-09-18
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$74.2M
2024 Medicare Part D Spend$25.8M
2024 Medicaid Spend$48.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel